Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives $106.08 Average PT from Brokerages
Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) have received a consensus recommendation of “Hold” from the fifteen brokerages that are presently covering the company, Marketbeat.com reports. Nine equities research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation […]
Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) have received a consensus recommendation of “Hold” from the fifteen brokerages that are presently covering the company, Marketbeat.com reports. Nine equities research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation […]
